Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 28;4(4):57-65.
doi: 10.46234/ccdcw2022.009.

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021

Dan Wu  1 , Yanyang Zhang  2 , Lin Tang  1 , Fuzhen Wang  1 , Ying Ye  2 , Chao Ma  1 , Hui Zheng  1 , Wenzhou Yu  1 , Lei Cao  1 , Yifan Song  1 , Abuduwaili Reyimu  3   4 , Xiaoxiao Zhang  2 , Haifeng Wang  1 , Yifei Nie  2 , Mingxia Lu  2 , Muge Qi  2 , Jun Li  2 , Ruolin Wang  2 , Kaichao Yang  2 , Changshuang Wang  2 , Lawrence Everett Rodewald  1 , Geroge Fu Gao  1 , Zhijie An  1 , Zundong Yin  1
Affiliations

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021

Dan Wu et al. China CDC Wkly. .

Abstract

What is already known about this topic?: Effectiveness of China's 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). During an outbreak in Guangdong, inactivated vaccine effectiveness (VE) against the Delta variant was 70% for symptomatic infection and 100% for severe COVID-19. However, separate or combined VE estimates for the two inactivated vaccines against Delta are not available.

What is added by this report?: In an outbreak that started in a hospital, VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant were 51%, 61%, and 82%. Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%. VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar, and partial vaccination was ineffective.

What are the implications for public health practice?: Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Completion of the completed primary vaccination with two doses is necessary for protection from Delta.

Keywords: Dietary Exposure; Fipronil; Pesticides; Total Diet Study.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. COVID-19 Vaccine Technical Working Group Technical vaccination recommendations for COVID-19 vaccines in China (First Edition) China CDC Wkly. 2021;3(21):459–61. doi: 10.46234/ccdcw2021.083. - DOI - PMC - PubMed
    1. Liu FF, Zheng CJ, Wang LP, Geng MJ, Chen H, Zhou S, et al Interpretation of the protocol for prevention and control of COVID-19 in China (Edition 8) China CDC Wkly. 2021;3(25):527–30. doi: 10.46234/ccdcw2021.138. - DOI - PMC - PubMed

    1. National Health Commission of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8). http://www.gov.cn/zhengce/zhengceku/2021-04/15/content_5599795.htm. [2022-1-10]. (In Chinese).

    1. Al Kaabi N, Zhang Y, Xia S, Yang YK, Al Qahtani MM, Abdulrazzaq N, et al Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45. doi: 10.1001/jama.2021.8565. - DOI - PMC - PubMed

    1. Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JDP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780. [2021-4-11].

LinkOut - more resources